Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
MI

NASDAQ · MIST

Milestone Pharmaceuticals Inc.

Healthcare · Biotechnology

$0.89

Down-$0.04 (-4.15%)

Updated Sep 17, 2026, 3:28 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
252.53M
P/E ratio
-6.21
Dividend yield
0.00%
52-week range
$0.90 – $2.34
Volume
1.57M
Avg. volume
2.14M

Price performance

MIST price history

1M range · 20 trading sessions · Daily adjusted prices

MIST closed at $0.89 after 20 trading sessions, down 17.67% for the selected period.

Last close
$0.89
Period change
-17.67%
Period low
$0.89
Period high
$1.21
Daily close
View OHLC price history
MIST OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$0.93$0.94$0.8841$0.88921.57M
Sep 15, 2026$0.9682$0.9732$0.90$0.92771.95M
Sep 14, 2026$0.99$1.035$0.9401$0.94942.58M
Sep 11, 2026$1.06$1.081$0.98$0.98013.32M
Sep 10, 2026$1.07$1.08$1.05$1.051.11M
Sep 9, 2026$1.13$1.14$1.07$1.071.31M
Sep 8, 2026$1.20$1.215$1.12$1.1251.79M
Sep 4, 2026$1.21$1.26$1.195$1.201.59M
Sep 3, 2026$1.22$1.26$1.195$1.212.03M
Sep 2, 2026$1.14$1.185$1.14$1.18767.74K
Sep 1, 2026$1.14$1.155$1.115$1.141.02M
Aug 31, 2026$1.17$1.17$1.14$1.161M
Aug 28, 2026$1.20$1.205$1.14$1.16865.69K
Aug 27, 2026$1.18$1.255$1.18$1.191.56M
Aug 26, 2026$1.17$1.1872$1.125$1.18727.11K
Aug 25, 2026$1.06$1.17$1.045$1.161.71M
Aug 24, 2026$1.06$1.06$1.02$1.041.56M
Aug 21, 2026$1.07$1.07$1.03$1.0551.92M
Aug 20, 2026$1.09$1.1291$1.02$1.032.18M
Aug 19, 2026$1.09$1.125$1.07$1.082.33M

Latest MIST news

The latest Smart Investors Daily articles mentioning MIST.

Stock researchCompany · Overview

MIST research

Overview

Company profile and research snapshot.

Company profile

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.00
Implied upside
—
Analysts
—
MIST recent ratings
DateFirmRatingTarget
Sep 3, 2026HC Wainwright & Co.Buy—
Aug 20, 2026Cantor FitzgeraldOverweight—
May 14, 2026Wells FargoOverweight—
Jan 6, 2026HC Wainwright & Co.Buy—
Dec 16, 2025Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone Pharmaceuticals MONTREAL and CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that China’s National Medical Products Adminis

Yahoo · Sep 2, 2026

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate in, the following upcoming investor conferences. Conference Details Wells Fargo 21st Annual Healthcare Conference Format:Fireside chat and 1x1sPresentation Date:September 8, 2026Time:1:30 pm ETLocation:Bos

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By